CRG is providing turnkey build-to-suit services to complete the new R&D facility for Pfizer in Chesterfield, Missouri. CRG is collaborating with Clayco, the design-builder on the project, for this office and laboratory space.
The dual-purpose structure will be comprised of 285,000 square feet of laboratory and office space. The design partnership of Forum Studio and Ewing Cole merged the expertise and talents of both firms where the unique combination of both research and development labs combined with office and meeting spaces creates one of the most progressive facilities in the pharma industry. The architecture, landscape design, engineering, interior and lab/process was also designed by Forum and EwingCole.
The new campus will be owned by Pfizer and will bring together more than 450 employees who currently work at multiple locations that the company leases in the St. Louis area. Pfizer expects to hire an additional 80 employees over the coming years to support research at the site. Construction is expected to be complete by mid-2019.
Representatives from Clayco, alongside Pfizer officials and local dignitaries, broke ground on the project June 27, 2017. When complete, the facility will provide approximately 285,000 square feet of R&D space to house Pfizer’s BioTherapeutics Pharmaceutical Sciences group and enabling partners. New state-of-the-art features of the campus will include a floor plan that provides flexible laboratory layouts, scientific casework and utility hookups, open office and collaboration spaces and increased conferencing technologies where researchers can collaborate.